Suppr超能文献

相似文献

1
Engineering host cell lines to reduce terminal sialylation of secreted antibodies.
MAbs. 2010 Sep-Oct;2(5):519-27. doi: 10.4161/mabs.2.5.13078. Epub 2010 Sep 1.
3
Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines.
J Immunol Methods. 2016 Jan;428:30-6. doi: 10.1016/j.jim.2015.11.009. Epub 2015 Nov 26.
4
Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.
Mol Immunol. 2007 Mar;44(7):1524-34. doi: 10.1016/j.molimm.2006.09.005. Epub 2006 Oct 11.
5
Fc glycan sialylation of biotherapeutic monoclonal antibodies has limited impact on antibody-dependent cellular cytotoxicity.
FEBS Open Bio. 2021 Nov;11(11):2943-2949. doi: 10.1002/2211-5463.13267. Epub 2021 Oct 19.
6
Modulating IgG effector function by Fc glycan engineering.
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3485-3490. doi: 10.1073/pnas.1702173114. Epub 2017 Mar 13.
7
Impact of Fc N-glycan sialylation on IgG structure.
MAbs. 2019 Nov-Dec;11(8):1381-1390. doi: 10.1080/19420862.2019.1655377. Epub 2019 Sep 2.
9
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12669-74. doi: 10.1073/pnas.1108455108. Epub 2011 Jul 18.
10
Sialyllactose supplementation enhances sialylation of Fc-fusion glycoprotein in recombinant Chinese hamster ovary cell culture.
J Biotechnol. 2024 Sep 10;392:180-189. doi: 10.1016/j.jbiotec.2024.07.016. Epub 2024 Jul 20.

引用本文的文献

1
Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab.
BioDrugs. 2024 Jul;38(4):571-588. doi: 10.1007/s40259-024-00662-5. Epub 2024 Jun 18.
2
Antibodies as clinical tools for tuberculosis.
Front Immunol. 2023 Dec 14;14:1278947. doi: 10.3389/fimmu.2023.1278947. eCollection 2023.
3
Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation.
Biochim Biophys Acta Gen Subj. 2023 Nov;1867(11):130448. doi: 10.1016/j.bbagen.2023.130448. Epub 2023 Aug 29.
4
Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants.
Antibodies (Basel). 2022 Nov 20;11(4):73. doi: 10.3390/antib11040073.
5
Impact of IgG1 N-glycosylation on their interaction with Fc gamma receptors.
Curr Res Immunol. 2020 Jun 27;1:23-37. doi: 10.1016/j.crimmu.2020.06.001. eCollection 2020 Dec.
7
Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein.
ACS Pharmacol Transl Sci. 2021 Jul 29;4(4):1349-1361. doi: 10.1021/acsptsci.1c00058. eCollection 2021 Aug 13.
8
Fc glycan sialylation of biotherapeutic monoclonal antibodies has limited impact on antibody-dependent cellular cytotoxicity.
FEBS Open Bio. 2021 Nov;11(11):2943-2949. doi: 10.1002/2211-5463.13267. Epub 2021 Oct 19.
9
On the Use of Surface Plasmon Resonance Biosensing to Understand IgG-FcγR Interactions.
Int J Mol Sci. 2021 Jun 21;22(12):6616. doi: 10.3390/ijms22126616.

本文引用的文献

1
Optimal and consistent protein glycosylation in mammalian cell culture.
Glycobiology. 2009 Sep;19(9):936-49. doi: 10.1093/glycob/cwp079. Epub 2009 Jun 3.
2
Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
Curr Opin Immunol. 2008 Aug;20(4):471-8. doi: 10.1016/j.coi.2008.06.007. Epub 2008 Jul 17.
3
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.
Science. 2008 Apr 18;320(5874):373-6. doi: 10.1126/science.1154315.
4
Antibody therapeutics: isotype and glycoform selection.
Expert Opin Biol Ther. 2007 Sep;7(9):1401-13. doi: 10.1517/14712598.7.9.1401.
5
Diversity in cell surface sialic acid presentations: implications for biology and disease.
Lab Invest. 2007 Sep;87(9):851-7. doi: 10.1038/labinvest.3700656. Epub 2007 Jul 16.
6
Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain.
Biotechnol Prog. 2007 Jul-Aug;23(4):964-71. doi: 10.1021/bp070118k. Epub 2007 Jun 16.
7
Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.
Expert Opin Biol Ther. 2006 Nov;6(11):1161-73. doi: 10.1517/14712598.6.11.1161.
8
Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.
Mol Immunol. 2007 Mar;44(7):1524-34. doi: 10.1016/j.molimm.2006.09.005. Epub 2006 Oct 11.
9
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.
Science. 2006 Aug 4;313(5787):670-3. doi: 10.1126/science.1129594.
10
Current and future issues in the manufacturing and development of monoclonal antibodies.
Adv Drug Deliv Rev. 2006 Aug 7;58(5-6):707-22. doi: 10.1016/j.addr.2006.05.002. Epub 2006 May 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验